87 related articles for article (PubMed ID: 17992118)
1. Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.
Reichle A; Vogt T; Coras B; Terheyden P; Neuber K; Trefzer U; Schultz E; Berand A; Bröcker EB; Landthaler M; Andreesen R
Melanoma Res; 2007 Dec; 17(6):360-4. PubMed ID: 17992118
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.
Reichle A; Bross K; Vogt T; Bataille F; Wild P; Berand A; Krause SW; Andreesen R
Cancer; 2004 Nov; 101(10):2247-56. PubMed ID: 15470711
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors.
Vogt T; Hafner C; Bross K; Bataille F; Jauch KW; Berand A; Landthaler M; Andreesen R; Reichle A
Cancer; 2003 Nov; 98(10):2251-6. PubMed ID: 14601096
[TBL] [Abstract][Full Text] [Related]
4. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.
Young SD; Whissell M; Noble JC; Cano PO; Lopez PG; Germond CJ
Clin Cancer Res; 2006 May; 12(10):3092-8. PubMed ID: 16707607
[TBL] [Abstract][Full Text] [Related]
6. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Spieth K; Kaufmann R; Gille J
Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults.
Reichle A; Vogt T; Kunz-Schughart L; Bretschneider T; Bachthaler M; Bross K; Freund S; Andreesen R
Br J Haematol; 2005 Mar; 128(5):730-2. PubMed ID: 15725096
[No Abstract] [Full Text] [Related]
8. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Morawek L; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma.
Coras B; Hafner C; Reichle A; Hohenleutner U; Szeimies RM; Landthaler M; Vogt T
Arch Dermatol; 2004 Dec; 140(12):1504-7. PubMed ID: 15611430
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Hauschild A; Agarwala SS; Trefzer U; Hogg D; Robert C; Hersey P; Eggermont A; Grabbe S; Gonzalez R; Gille J; Peschel C; Schadendorf D; Garbe C; O'Day S; Daud A; White JM; Xia C; Patel K; Kirkwood JM; Keilholz U
J Clin Oncol; 2009 Jun; 27(17):2823-30. PubMed ID: 19349552
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
15. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
18. Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes.
Kuklińska AM; Musiał WJ; Kamiński KA; Kralisz P; Modrzejewski W; Sobkowicz B; Dobrzycki S; Stec S; Wojtkowska I
Rocz Akad Med Bialymst; 2005; 50():339-42. PubMed ID: 16358997
[TBL] [Abstract][Full Text] [Related]
19. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
20. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Walter I; Schulz U; Vogelhuber M; Wiedmann K; Endlicher E; Klebl F; Andreesen R; Herr W; Ghibelli L; Hackl C; Wiest R; Reichle A
Med Oncol; 2017 Nov; 34(12):192. PubMed ID: 29098441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
